Prostate Cancer and Prostatic Diseases

Article	Citations
In regard to Boeri et al. ‘Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience’	129
Plant-based diets to reduce prostate cancer risk and improve prostate cancer outcomes—ready for prime time?	91
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?	74
Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer—exploratory analysis of LATITUDE study	53
Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer	51
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging	49
When precision meets prostate cancer: the rising role of HIFU focal therapy	45
Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer	45
PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer	42
The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature	41
Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) during robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies	36
Comparison of Retzius-sparing and conventional robot-assisted laparoscopic radical prostatectomy regarding continence and sexual function: an updated meta-analysis	35
Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors	35
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	32
Advancing the treatment of localized prostate cancer with MR-guided radiotherapy	31
Usefulness of podcasts to provide public education on prostate cancer genetics	30
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer	30
Goodbye and thanks for the memories	30
Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer	28
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer	27
Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications	27
Can there be consensus on whether vasectomy is a prostate cancer risk factor?	26
Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England	25
Enucleation of the prostate as retreatment for recurrent or residual benign prostatic obstruction: a systematic review and a meta-analysis	25
Transcriptome subtyping of metastatic Castration Resistance Prostate Cancer (mCRPC) for the precision therapeutics: an in silico analysis	24

Understanding biochemical recurrence after radical prostatectomy: trust biology, not a number	23
Artificial intelligence for target prostate biopsy outcomes prediction the potential application of fuzzy logic	23
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review	23
Social determinants of health and surgical outcomes of minimally invasive radical prostatectomy: a national population-based study	23
Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN	23
Prostate cancer metastasis and health disparities: a systematic review	22
Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function	21
Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis	21
Prostate cancer genetic propensity risk score may modify the association between this tumour and type 2 diabetes mellitus (MCC-Spain study)	21
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	21
Sexual outcomes in men who have sex with men who underwent radical prostatectomy	21
Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries	21
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer	20
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis	20
Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series	20
Dietary interventions to improve body composition in men treated with androgen deprivation therapy for prostate cancer: a solution for the growing problem?	19
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415	19
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction	19
Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer – A propensity score analysis	19
More evidence that physical activity is beneficial for prostate cancer	19
Impact of medical treatment on storage and voiding LUTS, nocturia, and quality of life in men at risk for progression	19
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates	19
Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: a systematic review and meta-analysis of over 6500 cases	19
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)	18
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer	18
Nomograms in PCa: where do we stand	17
Radical prostatectomy without prostate biopsy based on a noninvasive diagnostic strategy: a prospective single-center study	17
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer	16
The association between occupational asbestos exposure with the risk of incidence and mortality from prostate cancer: a systematic review and meta-analysis	16
The impact of race on survival in metastatic prostate cancer: a systematic literature review	16
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men	16
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer	16
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy	15
EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy	15
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones	15
Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level	15
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis	15
Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: a propensity score-based study	15
Artificial intelligence applications in prostate cancer	15
Best of 2022 in prostate cancer and prostatic diseases	15
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials	15
Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative	14
Variation in communication of side effects in prostate cancer treatment consultations	14
Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions – an EAU-YAU study enhancing prostate cancer detection	14
Impact of diverticular disease on prostate cancer risk among hypertensive men	14
Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled cli	14
Concerns regarding prostate cancer screening guidelines in minority populations	14
Impact of peritoneal reconfiguration on lymphocele formation after robot-assisted radical prostatectomy with pelvic lymph node dissection: a systematic review and meta-analysis of randomized controlle	14
Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer	14
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)	14

Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	14
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis	14
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?	14
The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement	14
Comparison of perioperative and short-terms outcomes of en-bloc Holmium laser enucleation of the prostate (HoLEP) and robot-assisted simple prostatectomy: a propensity-score matching analysis	13
Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients	13
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine	13
Clinicogenomic characterization of prostate cancer liver metastases	13
Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases	13
Trends in pre-biopsy MRI usage for prostate cancer detection, 2007–2022	13
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer	13
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sens	13
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	13
Correction: Public interest in dietary supplements for prostate cancer prevention	12
Correction to: Advances in PSMA-targeted therapy for prostate cancer	12
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial	12
Statins and prostate cancer—hype or hope? The epidemiological perspective	12
Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer	12
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	12
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro	12
Germline alterations among Hispanic men with prostate cancer	12
Correction: The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction	12
Correction: Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE−/−:Ins2+/Akita mouse model	12
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	12
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer	12
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations	11
18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review	11
Serendipity for the intervention of COVID-19 and prostatic adenocarcinoma (PaC)	11
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting	11
The evolving standards of active surveillance monitoring	11
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	11
A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading	11
Focal therapy for prostate cancer—ready to be a standard of care?	11
Comparison of senhance and da vinci robotic radical prostatectomy: short-term outcomes, learning curve, and cost analysis	11
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	11
Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia	11
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer—a multicenter SEARCH cohort study	11
Association between genetic variations at 8q24 and prostate cancer risk in Mexican Men	11
Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020	10
MyProstateScore in men considering repeat biopsy: validation of a simple testing approach	10
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate	10
Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency	10
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure	10
Nerve-sparing radical prostatectomy using the neurovascular structure-adjacent frozen-section examination (NeuroSAFE): results after 20 years of experience	10
RE: “Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?”	10
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing	10
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings	10
Hyperglycemia and microRNAs in prostate cancer	10
Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy	10
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers	10
Radiotheranostics in advanced prostate cancer: Current and future directions	10
Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation	10
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy	9
The role of COVID-19 in prostate tissue inflammation: first pathological evidence	9
Length of positive surgical margins after radical prostatectomy: Does size matter? – A systematic review and meta-analysis	9
Effects of high-intensity interval training on cardiometabolic biomarkers in patients with prostate cancer undergoing active surveillance: a randomized controlled trial	9
Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men	9
Is BMI a reliable prognostic parameter in metastatic prostate cancer patients?	9
Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis	9
Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis	9
Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies	9
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	9
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study	9
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms	9
Prostate cancer in New York City: impact of neighborhood level social determinants of care	9
Hospital volume and outcomes after radical prostatectomy: a national population-based study using patient-reported urinary continence and sexual function	9
Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?	9
A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy	9
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions	8
Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis	8
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board	8
Developers-Doctor-patients: the artificial intelligence’s trifecta	8
The diagnostic yield of the Meares & Stamey test can be significantly improved by symptom-based patient selection and the experience of the test performer	8
From BPH to male LUTS: a 20-year journey of the EAU guidelines	8
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis	8
The microbiome and prostate cancer	8
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids	8
Statins and prostate cancer—hype or hope? The biological perspective	8
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry	8
Best of 2023 in Prostate Cancer and Prostatic Diseases	8

Awaiting the perfect diagnostic test: optimal prostate cancer care begins without a diagnosis	8
LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations	8
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer	8
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer	8
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer	8
The natural history of a delayed detectable PSA after radical prostatectomy	8
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations	8
Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate	8
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	8